XML 38 R26.htm IDEA: XBRL DOCUMENT v3.19.2
Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)
3 Months Ended 9 Months Ended
Sep. 28, 2016
USD ($)
Agreement
$ / shares
shares
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Sep. 30, 2018
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Proceeds from the issuance of common stock       $ 60,521,729 $ 56,585,035  
Revenues   $ 42,696,636 $ 727,375 125,502,807 $ 4,887,321  
Contract liabilities   $ 75,681,868   $ 75,681,868   $ 600
Type of Revenue [Extensible List]   arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember  
Common Stock Purchase Agreement | Amgen            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Agreement date Sep. 28, 2016          
Shares issued | shares 3,002,793          
Stock issued, price per share | $ / shares $ 7.16          
Collaboration and License agreements | Amgen            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Agreement date Sep. 28, 2016          
Number of agreements | Agreement 2          
Collaboration and License agreements | Amgen            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Cash received as due under collaboration agreement $ 35,000,000          
Proceeds from the issuance of common stock 21,500,000          
Collaboration and License agreements | Maximum | Amgen            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Option payments, and development, regulatory and sales milestone payments. $ 617,000,000          
AMG 890 (ARO-LPA) and ARO-AMG1 Agreement | Amgen            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenues   $ 0 $ 700,000 $ 300,000 $ 4,900,000  
Contract liabilities   0   0    
Contract assets   $ 0   $ 0    
Type of Revenue [Extensible List]   us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember